drugset / Trial / NCT01106287
Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the safety and tolerability of single doses of MK-0941 based on assessment of clinical and laboratory adverse experiences
Timeline
- Start
- 2009-10
- Primary completion
- 2010-01
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-0941 | Small molecule | 60 mg | Oral |
| Subject | MK-0941 | Small molecule | 80 mg | Oral |
| Subject | MK-0941 | Small molecule | 100 mg | Oral |
| Subject | MK-0941 | Small molecule | 120 mg | Oral |
| Subject | MK-0941 | Small molecule | 140 mg | Oral |